Istesso advances regenerative approach to muscle loss (opens in new tab)

Phase 2 trial of leramistat targets sarcopenia, a major driver of frailty and loss of independence in later life. Longevity is teaching us that preserving muscle may be just as important as extending lifespan. London-based regenerative medicine company Istesso has announced the start of a Phase 2 clinical trial of its lead candidate leramistat in […] The post appeared first on <a href="